Apeiron Therapeutics to Present Preclinical Data on PRMT5 Inhibitor GTA182 at AACR 2025 Annual Meeting
SAN FRANCISCO, CA, Mar. 25, 2025 – Apeiron Therapeutics (Apeiron), a precision oncology company leveraging state-of-the-art structural biology and AI-guided molecular modeling for drug discovery, today announced that preclinical data from its clinical-stage PRMT5-inhibitor program, GTA182, will be presented at the American Association for Cancer Research (AACR) 2025 Annual Meeting, taking place from April 25-30, 2025, in Chicago, IL.
GTA182, a potent and selective PRMT5 inhibitor, is currently being evaluated in ongoing Phase 1 clinical trials for patients with advanced MTAP-null solid tumors. The presentation will highlight preclinical findings supporting the potential of GTA182 as a targeted therapy for these patients.
Details of the AACR Presentation Abstracts
Title: GTA182: A potentially best-in-class, MTA –cooperative inhibitor for MTAP-deleted advanced solid tumors
Session Category: Experimental and Molecular Therapeutics
Presenting Author: Fred Aswad, Ph.D., Senior Vice President, Biology
Session Title: HDAC and Methyltransferase Inhibitors
Session Date and Time: April 29, 2025, 9:00 AM – 12:00PM CT
Published Abstract Number: 4229
All presentations and posters will be available to registered attendees for on-demand viewing on the AACR website. Upon release at AACR, Apeiron’s presentations will also be available on Apeiron’s website.
About GTA182
GTA182 is a proprietary small molecule discovered through Apeiron’s AI-guided drug discovery platform. Currently in Phase 1 clinical development, GTA182 demonstrated potent and selective inhibition of PRMT5, exhibiting over 100-fold selectivity for MTAP-deleted tumor cell lines. Importantly, GTA182 is brain-penetrant and has shown tumor growth inhibition and regression in in vivo preclinical models, including glioblastoma (GBM) and various non-CNS cancer models with MTAP deletions.
About Apeiron Therapeutics
Apeiron is redefining medical discovery through the integration of artificial intelligence, streamlining the drug development process from target selection to clinical trials. With a strategic prescence in the San Francisco Bay Area, Apeiron combines world-class talent and cutting-edge technologies to drive biomedical innovation. We are committed to advancing breakthrough therapies that address the most pressing unmet medical needs.
For more information, please visit https://www.apeiron-bio.com.
Media Contact:
media@apeiron-bio.com
Investor Contact:
Silinda Neou
Silinda@apeiron-bio.com